Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cellectis S.A
CLLS | US
1.83
USD-0.06
-3.42%
CLLS | US
About Cellectis S.A
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.83
Open
1.94
High
1.94
Low
1.83
Cellectis S.A. a clinical stage biotechnological company develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19 an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris France.
View LessCLLS | US
Risk
36.2
Sharpe
0.17
Luna's Score
40/100
Recommendation
Sell
Luna says (CLLS | US)
What's Working
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
36.8%1 month
36.2%3 months
47.3%6 months
57.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.29
Debt to equity
0.74
Debt to assets
0.27
Ent. to EBITDA
-3.90
Ent. to rev.
1.32
PEG
-
Other Fundamentals
EBITDA
-77.39M
MarketCap
191.88M
MarketCap(USD)
191.88M
Div. yield
-
Op. margin
-181.11
Erngs. growth
-
Rev. growth
374.90
Ret. on equity
-64.37
Short ratio
20.35
Short perc.
0.44
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.24
Range1M
0.48
Range3M
0.60
Volumes: Market Activity
Rel. volume
1.14
Price X volume
60.22K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.90 | - | Cheaper |
| Ent. to Revenue | 1.32 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.29 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 47.33 | - | Lower Risk |
| Debt to Equity | 0.74 | -1.23 | Expensive |
| Debt to Assets | 0.27 | 0.25 | Par |
| Market Cap | 191.88M | - | Emerging |
